B
Bullisch
Bullisch · 25%AXSM
$200.39
Szenariopreis
$143.985
-1.051 (-0.73%)Zum Schluss
Loading chart…
- Hoch
- 145.335
- Eröffnung
- 145.290
- Volumengewichteter Durchschnittskurs
- 143.77
- Volumen
- 878.99K
- Marktkap.
- 3.80B
- Tief
- 142.000
- Umsatz
- 126.38M
- EV/EBITDA, TTM
- -23.41
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
KI-Analyse of Axsome Therapeutics, Inc. (AXSM)
HaltenAxsome Therapeutics Inc is currently not a strong buy due to its low RSI of 15.938, indicating oversold conditions, and a significant recent price drop of 7.70% over the last five days. However, the company's revenue growth is promising, with a 46% year-over-year increase to $218.4 million in Q2, driven by the strong performance of its drug Auvelity. The main risk is the widening net loss per share, which stands at -0.99, indicating ongoing financial challenges. Therefore, while there are positive growth indicators, the current technical and financial situation suggests holding rather than buying.
Analystenbewertungen (2)
+45.53% Aufwärtspotenzial
Kaufen
2 Kaufen
0 Halten
0 Verkaufen
Aktuell: 143.99
Tief
153.00
Durchschnitt
209.54
Hoch
260.00
RBC Capital
Überdurchschnittlich
$295
2026-10-08
RBC Capital
2026-10-08
Kursziel
$295
Überdurchschnittlich
Deutsche Bank
Kaufen
$267
2026-09-29
Deutsche Bank
2026-09-29
Kursziel
$267
Kaufen
Morgan Stanley
Equal Weight
$247
2026-09-25
Morgan Stanley
2026-09-25
Kursziel
$247
Equal Weight
Truist
Kaufen
$285
2026-09-23
Truist
2026-09-23
Kursziel
$285
Kaufen
H.C. Wainwright
Kaufen
$290
2026-08-31
H.C. Wainwright
2026-08-31
Kursziel
$290
Kaufen
Bewertungskennzahlen
Das aktuelle erwartete KGV von Axsome Therapeutics, Inc. (AXSM) beträgt 32.15, verglichen mit dem 5-Jahres-Durchschnitt von 25.78.
Alphio-AI-Kursszenarien für AXSM
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die AXSM halten
Event-Zeitleiste
News
6.510-23FoolAI Stocks Attract Wall Street Attention Amid Growth Opportunities
7.510-16FoolInvestment Opportunities in Biotech Companies Amid AI Focus
5.010-12FoolAxsome's Auvelity Sales Surge as Alzheimer's Treatment Expands Market Potential
6.510-08FoolInvestment Comparison Between Axsome and Moderna
6.510-01FoolInvestment Comparison: Axsome vs. Vertex Pharmaceuticals
AXSM FAQ – beantwortet von Alphio AI
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Axsome Therapeutics Inc is currently not a strong buy due to its low RSI of 15.938, indicating oversold conditions, and a significant recent price drop of 7.70% over the last five days. However, the company's revenue growth is promising, with a 46% year-over-year increase to $218.4 million in Q2, driven by the strong performance of its drug Auvelity. The main risk is the widening net loss per share, which stands at -0.99, indicating ongoing financial challenges. Therefore, while there are positive growth indicators, the current technical and financial situation suggests holding rather than buying.
2 analysts cover AXSM: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 209.54.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.